Oculis
- Market cap
- 523.50M
- P/E (TTM)i
- -5.13
- P/Bi
- 1.99
- EPSi
- -2.27
- Div yieldi
- 0.00%
- 52W posi
- 1%
Anonymous reader poll. Unscientific, not investment advice.
About Oculis
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
- Founded
- 2016
- CEO
- Dr. Riad Sherif, M.D.
- Employees
- 60
- Headquarters
- Zug, Zug, Switzerland
- Fiscal year end
- 12-31
- Website
- oculis.com
Company profile
- Exchange
- US
- Symbol
- OCS
- Market-cap rank
- #3716
- Market cap
- 523.50M
- Float cap
- 444.23M
- Shares out
- 61.59M
- Float shares
- 52.26M
Sectors & themes
Quote time 2026-10-08 08:34:34 · For reference only, not investment advice and not tailored to your situation.